LaNova Medicines Secures RMB 300 Million in Series C1 Financing to Advance Cancer Therapy Pipeline
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the successful completion of...
Abbott Laboratories Posts 9.4% Q3 Sales Growth, Driven by Medical Devices and Pharmaceuticals
Abbott Laboratories (NYSE: ABT), a U.S.-based healthcare giant, has reported its financial results for the...
Chengdu Baiyu Pharmaceutical Strikes Licensing Deal with Novartis for Unannounced Anti-Tumor Asset
Chengdu Baiyu Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, has entered into a licensing agreement...
Cryofocus Medtech Partners with Guangzhou Medical University Hospital for Cryoballoon Ablation R&D
Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the...
Kintor Pharmaceutical Initiates Phase II/III Trial for KX-826 Tincture 1.0% in Treating Male Androgenetic Alopecia
Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the commencement...
Novocure’s Optune Lua Wins FDA Approval for mNSCLC Treatment in Combination with Immunotherapies
Novocure (NASDAQ: NVCR), a Swiss firm renowned for its pioneering Tumor Treating Fields (TTFields) cancer...
Servier and HUST Forge Partnership to Cultivate Innovative Therapies through SHINEDocs Program
French pharmaceutical company Servier has joined forces with Huazhong University of Science and Technology (HUST),...
Innovent Biologics’ Picankibart Achieves Positive Results in Phase II UC Study
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration
Bayer AG (ETR: BAYN), a German multinational pharmaceutical and life sciences giant, has announced the...
Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ:...
Johnson & Johnson’s Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial
Johnson & Johnson (J&J, NYSE: JNJ), a US pharmaceutical giant, has reported encouraging outcomes from...
NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud
The National Healthcare Security Administration (NHSA) has issued a notification aimed at standardizing the management...
Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024
On October 16, 2024, Shanxi Province’s drug procurement platform announced a notice regarding the submission...
Alphamab Oncology and CSPC Pharma’s KN026 Phase III Trial for Breast Cancer Gets NMPA Approval
Alphamab Oncology (HKG: 9966) and CSPC Pharma (HKG: 1093) have jointly announced that their Phase...
Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement
Boehringer Ingelheim (BI), a leading German pharmaceutical company, has joined forces with the World Health...
J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress
Johnson & Johnson (J&J, NYSE: JNJ) has released its financial report for the third quarter...
Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biotech company based in...
Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced...
Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...
Innovec Biotherapeutics’ IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China’s CDE
Beijing InnoVec Biotherapeutics Inc., a leading gene therapy company based in China, has announced that...